Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

D-Pharm Selects Tigermed for Trial of Stroke Drug

publication date: Nov 4, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
D-Pharm of Israel will entrust Hangzhou Tigermed Consulting Co. with a Phase III China clinical trial of its stroke treatment. Tigermed will also be in charge of China regulatory filings for DP-b99, a neuroprotective drug. Wanbang Biopharma, which will market the drug in China for D-Pharm, also signed the contract. More details....

Stock Symbol: (TASE: DPRM)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...